Cancer Immunotherapy Program Event Listing

1 - 1 of 1

The CAR-T Revolution 3 Years After FDA Approval

Torie CART

Three years after FDA approval of the first CAR-T therapy, Dr. Grupp will review outcomes data and provide an update on advancements and new trials in the field of cancer immunotherapy for patients with relapsed acute lymphoblastic leukemia (ALL).

Date:
Dec 15, 2020 from 5 p.m. - 6:30 p.m. (ET)